Medivir announces the successful completion of the pre-clinical safety studies for MIV-818 to enable the start of phase I clinical trials in 2018.
MIV-818 is Medivir’s liver-targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC) and other forms of liver cancer. It is the first development project to emerge from Medivir’s in-house drug discovery efforts in oncology.
Now, Medivir intends to make the necessary regulatory submissions during the first half of 2018, and to start the first clinical trials of MIV-818 during the second half of 2018.
“Patients with HCC and other forms of liver cancer are in urgent need of new treatment options. MIV-818 has been designed to deliver high levels of the active form of the drug to the liver after oral administration, while minimizing its exposure elsewhere in the body. This targeted approach to cancer chemotherapy has the potential to be an important new treatment for liver cancers, either alone or in combination with other therapeutic modalities”, said Richard Bethell, Medivir’s Chief Scientific Officer.
Photo of Richard Bethell: Medivir